Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
None
FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer

FOLFOX4 plus Avastin has been suggested as firstline regimen for advanced colorectal cancer by NCCN, a new angiogenesis inhibitor, known as Endostar(Recombinant Human Endostatin

measurable disease
avastin
lung cancer
  • 12 views
  • 07 Nov, 2020
  • 1 location
None
Bevacizumab in Advanced Hepatocellular Carcinoma

liver cancer. Bevacizumab is an angiogenesis inhibitor already successfully used in patients with colorectal and renal cancers.

biliary tract cancer
primary liver cancer
neutrophil count
bevacizumab
hepatitis
  • 14 views
  • 07 Nov, 2020
  • 1 location
None
A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer

To verify the clinical efficacy and safety of bevacizumab in treating local advanced cervical cancer, present study was designed to investigate the clinical results of bevacizumab combined with concurrent chemoradiotherapy (CCRT) in local advanced cervical cancer

  • 1 views
  • 25 Jan, 2021
  • 1 location
None
A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Pazopanib is an angiogenesis inhibitor targeting VEGFR-1, -2, and -3; PDGFR- and -; and the receptor c-Kit, and is indicated for the treatment of subjects with advanced renal cell carcinoma (RCC

measurable disease
metastatic soft tissue sarcoma
KIT
soft tissue sarcoma
cancer
  • 1 views
  • 01 May, 2021
  • 1 location
None
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis

safe, alternative angiogenesis inhibitor for adolescents and young women with endometriosis. This trial proposes a novel, non-hormonal, non-surgical therapeutic approach aimed at alleviating the pain

  • 4 views
  • 25 Mar, 2021
  • 2 locations
None
Oxaliplatin Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer

Chinese phase III clinical trial in advanced non-small-cell lung cancer, endostar--a new angiogenesis inhibitor prolonged the overall survival, time to progression and improved response rate

  • 1 views
  • 07 Nov, 2020
  • 1 location
None
Study of Recombinant Human Endostatin Combined With Temozolomide and Irinotecan in Recurrent Gliomas

months. Recombinant human endostatin (rh-ES) is an endogenous broad-spectrum angiogenesis inhibitor that has been shown to significantly improve therapeutic efficacy when combining with conventional

  • 0 views
  • 27 Jan, 2021
  • 1 location
None
Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas

angiogenesis inhibitor that has been shown to significantly improve therapeutic efficacy when combining with conventional chemotherapy agents in non-small-cell lung cancer, breast cancer and melanoma.Previous

  • 0 views
  • 24 Mar, 2021
  • 1 location
None
TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer

, however, induces a hypoxic micro-environment, which increases neo-angiogenesis, and may promote early progression. For this reason, efficacy may be improved by associating TACE with an angiogenesis

  • 6 views
  • 23 Jan, 2021
  • 1 location
None
Improved Assessment of Response in Metastatic Renal Cell Carcinoma Using Spectral-CT

The incidence of renal cancer in Denmark is approximately 900 new cases per year. Untreated, the 5-year survival rate for metastatic renal cancer (mRCC) is 2%. Development of angiogenesis inhibitors (AI) and check-point immunotherapy (CPI) has improved survival. Treatment efficacy is evaluated by CT scans, using RESIST 1.1 (Response Evaluation …

  • 4 views
  • 24 Jan, 2021
  • 1 location